Literature DB >> 9988100

A heroin-, but not a cocaine-expecting, self-administration state preferentially alters endogenous brain peptides.

S L Cappendijk1, Y L Hurd, I Nylander, J M van Ree, L Terenius.   

Abstract

The purpose of the current study was to assess neuropeptidergic alterations during a phase of the drug addiction cycle associated with drug craving as compared to a time period when the drug had been recently self-administered. Male Wistar rats were allowed to self-administer cocaine, heroin or saline for 6 h for 5 consecutive days. Immediately following the last self-administration session ('acute drug on board' state), and just before the next scheduled session ('drug expecting' state), the animals were decapitated and the levels of dynorphin A and B, [Met5]- and [Leu5]-enkephalin and substance P were measured in different brain areas. During the 'acute drug on board' state, peptide levels in animals that self-administered heroin or cocaine were not significantly changed. In contrast, during the 'drug expecting' state, heroin-treated animals had increased levels of dynorphin A, dynorphin B and [Met5]-enkephalin in the caudal striatum as compared to the cocaine- and saline-treated animals, and the level of [Leu5]-enkephalin was increased as compared to the cocaine-treated group. In the septum, an increase of [Met5]-enkephalin and substance P was observed in the animals expecting heroin as compared to the saline- and/or cocaine-treated animals. In the caudal striatum, substance P levels were elevated in the heroin- and cocaine-expecting animals. In conclusion, heroin, as compared to cocaine, appears to have a more pronounced effect on dynorphin, enkephalin and substance P levels in the caudal striatum and septum, especially during periods when self-administration of the drug is expected.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988100     DOI: 10.1016/s0014-2999(98)00874-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

Review 2.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

3.  Chronic morphine treatment modulates the extracellular levels of endogenous enkephalins in rat brain structures involved in opiate dependence: a microdialysis study.

Authors:  Magdalena Mas Nieto; Jodie Wilson; Annie Cupo; Bernard P Roques; Florence Noble
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

Review 4.  Traumatic Stress-Induced Vulnerability to Addiction: Critical Role of the Dynorphin/Kappa Opioid Receptor System.

Authors:  Claire Leconte; Raymond Mongeau; Florence Noble
Journal:  Front Pharmacol       Date:  2022-04-27       Impact factor: 5.988

Review 5.  A role for brain stress systems in addiction.

Authors:  George F Koob
Journal:  Neuron       Date:  2008-07-10       Impact factor: 17.173

6.  Long-term antagonism of κ opioid receptors prevents escalation of and increased motivation for heroin intake.

Authors:  Joel E Schlosburg; Timothy W Whitfield; Paula E Park; Elena F Crawford; Olivier George; Leandro F Vendruscolo; George F Koob
Journal:  J Neurosci       Date:  2013-12-04       Impact factor: 6.167

Review 7.  A unified framework for addiction: vulnerabilities in the decision process.

Authors:  A David Redish; Steve Jensen; Adam Johnson
Journal:  Behav Brain Sci       Date:  2008-08       Impact factor: 21.357

Review 8.  The role of enkephalinergic systems in substance use disorders.

Authors:  Lauren G Rysztak; Emily M Jutkiewicz
Journal:  Front Syst Neurosci       Date:  2022-08-05

9.  Altered Accumbal Dopamine Terminal Dynamics Following Chronic Heroin Self-Administration.

Authors:  Brianna E George; Monica H Dawes; Emily G Peck; Sara R Jones
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.